The Potential of Devices for HFpEF

Andrew Coats, Stefan Anker


The 2016 ESC/HFA HF guidelines list the very many drug and device therapies that are proven to be beneficial in terms of life prolongation and hospitalisation prevention for HFrEF. The list of recommended therapies or devices for HFpEF and HFmrEF is limited to diuretics and the management of comorbidities and so far there is no clinical evidence for an electrical or mechanical device for HFpEF. The Cardiac Contractility Modulation (CCM) device that may have a role in selected HFrEF and HFmrEF patients has been reviewed in another paper in this issue but here we survey the results so far of a novel device for patients with HFpEF. Despite lagging many years behind HFrEF, HFpEF patients are now being targeted with novel devices with the potential to improve symptoms, improve quality of life, reduce hospitalization and delay progression of the syndrome. The front-runner is a novel inter-atrial left atrial pressure decompression device the Corvia IASD, which currently enrolling patients in a randomized trial. This device is a CE-marked investigational, non- surgical transcatheter implant designed to provide continuous and dynamic decompression of the left atrium, in an effort to reduce symptoms, HF hospitalizations, and improve quality of life as well as potentially slowing the progression of HFpEF.


Heart Failure; HFpEF; inter-atrial shunt; devices

Full Text:

448 HTML


Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, et al.

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail. 2016 Aug;18(8):891-975. doi: 10.1002/ejhf.592.

Kaye D, Malek F, Gustafsson F, et al. Initial Six Month Results of a Novel Inter- atrial Shunt Therapy for Heart Failure with Preserved Ejection Fraction. Presented at ACC 2014.

Kaye D, Shah SJ, Borlaug BA, Gustafsson F, Komtebedde J, Kubo S, Magnin C, Maurer MS, Feldman T, Burkhoff D. Effects of an interatrial shunt on rest and exercise hemodynamics: results of a computer simulation in heart failure. J Card Fail. 2014 Mar; 20(3): 212–21. doi:10.1016/j. cardfail.2014.01.005.

Søndergaard L, Reddy V, Kaye D, et al. Transcatheter Treatment of Heart Failure with Preserved or Mildly Reduced Ejection Fraction Using a Novel Interatrial Implant to Lower Left Atrial Pressure. Eur J Heart Failure 2014; 16: 796–801.

Malek F, Neuzil P, Gustafsson F, et al. Clinical Outcome of Transcatheter Treatment of Heart Failure with Preserved or Mildly Reduced Ejection Fraction Using a Novel Implant. International Journal of Cardiology 2015; 187: 227–28.

Hasenfuβ G, Gustafsson F, Kaye D, et al. Rationale and Design of the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (Reduce LAP- HF) Trial. J Card Fail 2015; 21(7): 594–600.

Hasenfuß G, Hayward C, Burkhoff D, et al. A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP- HF): a multicentre, open- label, single- arm, phase 1 trial. Lancet. 2016 Mar 26; 387(10025): 1298–304. doi:10.1016/S0140- 6736(16)00704- 2.

Feldman T, Komtebedde J, Burkhoff D, et al. Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure: Rationale and Design of the Randomized Trial to REDUCE Elevated Left Atrial Pressure in Heart Failure (REDUCE LAP-HF I) Circ. Heart Fail. 2016; 9: e003025. doi:10.1161/CIRCHEARTFAILURE.116.003025.

Shewan L.G., Coats A.J.S., Henein M. Requirements for Ethical Publishing in Biomedical Journals. International Cardiovascular Forum Journal. 2015;2:2.


Copyright (c) 2017 Andrew Coats

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.